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Abstract. In Alzheimer’s disease (AD), cognition and function are only moderately correlated in cross-sectional studies, and
studies of their longitudinal association are less common. One potential non-cognitive contributor to function is depression,
which has been associated with poorer clinical outcomes. The current study investigated longitudinal associations between
functional abilities, cognitive status, and depressive symptoms in AD. 517 patients diagnosed with probable AD and enrolled in
The Multicenter Study of Predictors of Disease Course in Alzheimer’s Disease were included. Patients were followed at 6-month
intervals over 5.5 years. Longitudinal changes in the Blessed Dementia Rating Scale, modified Mini-Mental State Exam, and
the depression subscale of the Columbia University Scale for Psychopathology in AD were examined in a multivariate latent
growth curve model that controlled for gender, age, education, and recruitment site. Results showed that cognition and function
worsened over the study period, whereas depressive symptoms were largely stable. Rates of change in cognition and function
were correlated across participants and coupled within participants, indicating that they travel together over time. Worse initial
cognitive status was associated with faster subsequent functional decline, and vice versa. Higher level of depressive symptoms
was associated with worse initial functioning and faster subsequent cognitive and functional decline. These findings highlight
the importance of both cognitive and psychiatric assessment for functional prognosis. Targeting both cognitive and depressive
symptoms in the clinical treatment of AD may have incremental benefit on functional abilities.
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INTRODUCTION
Alzheimer’s disease (AD) is an age-related neu-
rodegenerative disorder characterized by declines in
both cognitive skills and functional abilities. Despite
an intuitive link between cognition and function, these
variables are only moderately correlated in cross-
sectional analyses [1], and longitudinal studies of their
association in patients with AD are less common.
∗Correspondence to: Yaakov Stern, Sergievsky Center/Taub
Institute, Columbia University, 630 168th Street, P & S Box 16,
New York, NY 10032, USA. Tel.: +1 212 342 1350; Fax: +1 212
342 1838; E-mail: ys11@columbia.edu.
Understanding the relationship between cognition and
function over the course of AD has important implica-
tions in terms of choosing outcomes in clinical trials,
predicting real-world function based on cognitive data,
and ascertaining clinical prognosis.
One potential non-cognitive contributor to func-
tional status is depression, which is associated with
increased risk of developing AD [2, 3]. Among indi-
viduals already diagnosed with AD, depression occurs
in up to 50% of patients and has been cross-sectionally
associated with worse functional abilities, independent
of cognitive status [4, 5]. Depression may also predict
future cognitive decline in AD [6]. The influence of
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depression on the clinical course of AD is uncertain and
may differ between individuals. Thus, there is a need
for large, longitudinal studies of depressive symptoms,
cognition, and function in AD.
A recent population-based study of 328 AD patients
reported that rates of change in function correlated
with rates of change in cognitive and neuropsychi-
atric symptoms over 3.8 years [7]. However, this study
only examined between-person associations between
rates of change, and the use of mixed effects mod-
els precluded an examination of multiple trajectories
within a single, controlled model. Further, only global
neuropsychiatric functioning was measured rather
than specific symptoms (e.g., depressive) despite evi-
dence that different neuropsychiatric symptom clusters
exhibit distinct trajectories in AD [8].
Previous studies from our group using data from
the Multicenter Study of Predictors of Disease Course
in Alzheimer’s Disease (“Predictors Study”) [9, 10]
have shown that compared to psychosis and behavioral
disturbance, depressive symptoms do not commonly
appear de novo during the course of AD [11]. Further,
depressive symptoms decrease with AD progression
[12]. The present study aimed to extend these find-
ings to an examination of the influence of depressive
symptoms on functional ability, an important clinical
outcome. Specifically, we examined the trajectories of
functional, cognitive, and depressive symptoms in a
large sample of AD patients followed over 5.5 years
using multivariate latent growth curve modeling.
MATERIAL AND METHODS
Participants and procedures
The present sample included 517 patients diagnosed
with probable AD and enrolled in the Multicenter
Study of Predictors of Disease Course in Alzheimer’s
Disease. Local Institutional Review Boards at all
participating sites approved the study. Full study pro-
cedures are described elsewhere [9, 10]. In brief,
patients were recruited in two waves at outpatient
clinics and clinical research centers at four sites in
the United States and Europe: Columbia University
Medical Center (n = 208), Johns Hopkins School of
Medicine (n = 147), Massachusetts General Hospi-
tal (n = 124), and the Hoˆpital de la Salpeˆtrie`re in
Paris, France (n = 38). Diagnoses of probable AD were
made using NINCDS-ADRDA criteria [13] at con-
sensus conferences attended by at least two faculty
physicians specializing in dementia and one faculty
neuropsychologist. Complete inclusion and exclusion
criteria for the study have been described previously
[9, 10]. All patients were required to have mild demen-
tia, as defined by a Modified Mini-Mental State Exam
(mMMS) score ≥30 (see description of this measure
below), which is equivalent to a Folstein Mini-Mental
State Exam score ≥16. Exclusion criteria were evi-
dence for a cause of dementia other than Alzheimer’s
disease, parkinsonism, stroke, alcoholism, schizophre-
nia, schizoaffective disorder, and electroconvulsive
therapy within two years preceding study enrollment
or a history of 10 or more electroconvulsive treatments
in a single course.
Average age was 74.19 (SD = 8.45). Average level
of education was 13.72 (3.62). The sample comprised
43.1% males, 93.2% Caucasians, and 95.2% non-
Hispanics. 182 participants were reported to have taken
a prescription medication for dementia at some point
during the 5.5-year study period. The vast majority
(n = 176) of participants taking an anti-dementia med-
ication were recruited in the second wave (i.e., after
1997). Only six of the 252 participants recruited before
1997 were reported to have taken an anti-dementia
medication. 166 participants were reported to have
taken an antidepressant at some point during the study
period.
Participants were assessed prospectively at 6-month
intervals for up to 16 years. At least one follow-up
assessment was available for 96.52% of the present
sample. The average number of assessments was 10.10
(standard deviation = 5.85), indicating that the aver-
age participant was followed semiannually over 5
years. Only data from the first 12 occasions (5.5
years) were included in the present study in order to
maximize covariance coverage. Information on out-
come measures across the 12 occasions is provided in
Table 1. 193 participants were assessed with at least
one outcome measure at the 12th occasion. These par-
ticipants did not differ from the 324 participants who
were not assessed at the 12th occasion in terms of
age, education, race, ethnicity, or depressive symp-
toms. However, they exhibited lower cognition and
functioning at baseline, as assessed by the mMMS
(36.91 versus 38.84; t(512) = –3.364; p < 0.001) and
the Blessed Dementia Rating Scale (BDRS; 3.80 ver-
sus 2.86; t(435.695) = 5.296; p < 0.001), respectively.
Measures
Depressive symptoms were assessed at each
occasion with the Columbia University Scale for
L.B. Zahodne et al. / Coupled Change in AD 853
Table 1
Patient scores at each visit
BDRS mMMS CUSPAD depressed mood
Year n Mean SD n Mean SD n Mean SD
0 507 3.44 2.05 514 37.63 6.37 509 0.74 1.05
0.5 452 4.10 2.45 445 35.38 8.54 428 0.67 0.97
1 427 4.97 2.99 421 33.04 10.11 399 0.80 1.05
1.5 394 5.81 3.46 377 30.81 10.88 366 0.77 1.06
2 361 6.31 3.61 345 29.39 12.00 339 0.70 1.00
2.5 346 7.14 3.92 312 27.33 12.86 326 0.69 1.04
3 310 7.67 4.08 277 25.61 14.20 286 0.64 0.96
3.5 275 8.26 3.95 239 24.64 13.77 258 0.66 0.95
4 266 8.68 4.15 225 24.05 14.18 235 0.60 0.97
4.5 214 9.41 4.25 178 21.96 15.06 190 0.61 0.95
5 206 9.66 4.33 166 22.95 14.89 182 0.58 0.94
5.5 191 10.28 4.31 136 22.21 13.96 167 0.69 1.10
BDRS, Blessed Dementia Rating Scale (range: 0 to 16); mMMS, modified Mini Mental State Exam (range: 0 to
57); CUSPAD, Columbia Scale for Psychopathology in Alzheimer’s Disease (range: 0 to 4).
Psychopathology in AD (CUSPAD) [14]. The
CUSPAD is a semi-structured interview conducted
with an informant assessing the presence and sever-
ity of delusions, hallucinations, illusions, behavioral
disturbances, and depressive symptoms over the past
month. Only depressive symptom severity scores were
used in the present study. Scores range from 0 to 4,
with higher scores indicating greater psychopathology.
Good inter-rater reliability for concurrent ratings of the
depressive symptoms portion of a single interview has
been reported ( = 0.80) [14]. Separate models treating
the depressive symptoms variable as continuous versus
categorical were run. Importantly, there were no dif-
ferences in the patterns of associations between latent
variables in these models. Because a larger number
of fit indices are provided in the continuous variable
models, results from these models are presented.
Global cognitive status was evaluated at each occa-
sion with the mMMS [15]. In addition to items from
the Mini-Mental State Exam [16], the mMMS includes
items allowing for more comprehensive assessment
of working memory, calculation, recall of the current
and four previous presidents of the United States, con-
frontation naming, repetition, and visuoconstruction.
The scale was translated and modified for assessments
at the Paris site. Scores range from 0 to 57, with higher
scores indicating better cognitive functioning.
Functional abilities were assessed with the BDRS
[17]. The BDRS is a semi-structured interview con-
ducted with an informant that assesses a patient’s
difficulty performing various activities of daily living
for non-physical reasons. The sum of items specifi-
cally assessing instrumental (1–7) and basic (9–11)
activities of daily living were used in the present study.
Scores range from 0 to 16, with higher scores indicating
greater functional difficulty.
Statistical analysis
Data were analyzed in MPlus version 7 with a spe-
cial case of structural equation modeling often referred
to as latent growth curve (LGC) modeling using maxi-
mum likelihood estimation [18, 19]. Missing data were
managed with full information maximum likelihood
(FIML), which uses all available data for parameter
estimation. This approach accumulates and maximizes
casewise likelihood functions computed using all avail-
able data for each participant. Monte Carlo simulation
has shown that FIML produces unbiased and more effi-
cient estimates than alternative methods (e.g., listwise
deletion, pairwise deletion, and similar response pat-
tern imputation) [20]. Models carry the assumptions
of homogeneity of error variance and dependence of
errors within each domain (i.e., function, cognition,
depressive symptoms). A strength of LGC modeling
is that it allows the study of multiple outcomes over
time in a multivariate framework. The overall level
of (intercept) and amount of change in (slope) each
symptom type (i.e., functional, cognitive, depressive)
represented the key parameters. Additional informa-
tion regarding parameter estimation in multivariate
LGC and its application to the study of neurodegen-
erative disease are available elsewhere [18, 21]. Model
fit was assessed with the following, commonly-used
statistics: Chi square, Akaike information criterion
(AIC), sample size-adjusted Bayesian information cri-
terion (BIC), root mean square error of approximation
(RMSEA), comparative fit index (CFI), and Tucker-
Lewis index (TLI). Smaller values of chi square, AIC,
BIC, and RMSEA indicate better model fit. Values of
CFI and TLI that are closer to 1 indicate better fit.
Fit between nested models was compared statistically
using the chi square test.
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Model building proceeded in two broad stages.
First, the trajectories of the three variables of interest
were examined separately with unconditional univari-
ate growth curve models. To characterize the functional
forms of functional, cognitive, and depressive tra-
jectories, models that estimated only linear change
were statistically compared to those that estimated
both linear and quadratic change. Second, best-fitting
univariate models were combined into a single, condi-
tional multivariate model, in which obtained parameter
estimates control for all included variables. In this
model, correlations between initial levels and changes
in the symptoms independent of the covariates (i.e.,
gender, age, education in years, and recruitment site)
can be estimated. Within-person coupling of symp-
toms over time was examined via correlations between
occasion-specific residuals [22]. These correlations
reflect the relationship between state-like, occasion-
specific changes in the different symptom domains
after controlling for a person’s trait-like change trajec-
tories. For parsimony, correlations of occasion-specific
residuals were constrained to be equal across occasions
for each symptom domain pair. In addition, covari-
ate effects on both the overall levels of symptoms
(intercepts) as well as on symptom changes (slopes)
were examined. Covariates were centered to facili-
tate parameter interpretation. Specifically, values of 0
corresponded to age 74, 12 years of education, male
gender, and enrollment at the Columbia site.
RESULTS
Unconditional univariate models
Nested unconditional univariate models were
built separately for the three outcome variables.
In models allowing only linear change, functional
problems (slope estimate = 1.150; p < 0.001) and cog-
nitive symptoms (slope estimate = –4.783; p < 0.001)
worsened over the study period. In contrast, depres-
sive symptoms improved (slope estimate = –0.024;
p = 0.043). Allowing for curvilinear change signifi-
cantly improved model fit for functional problems
(χ2(4) = –438.77, p < 0.001), cognitive symptoms
(χ2(4) = –503.18, p < 0.001), and depressive symp-
toms (χ2(4) = –34.66, p < 0.001). Thus, models
including both linear and quadratic slopes were
retained for subsequent model building.
Parameter estimates in the best-fitting unconditional
univariate LGC models are shown in the upper panel
of Table 2. Intercepts (levels) refer to latent variables
derived from all 12 occasions that reflect estimated ini-
tial levels of the outcomes independent of the growth
process, not merely baseline scores. Linear slopes can
be interpreted as the constant rates of change over time.
Quadratic slopes can be interpreted as changes in the
rates of change over time. As shown in Fig.1, functional
problems and cognitive symptoms worsened over the
study period. This worsening of cognitive symptoms
was most dramatic early on and leveled out over time.
Although the model of depressive symptoms allowing
for curvilinear change fit the data better than the model
allowing only linear change, neither slopes reached sig-
nificance in the more complex model, indicating that
depressive symptoms were largely stable among the
sample as a whole. However, significant residual vari-
ances in both intercepts and slopes (all p’s < 0.001) in
all three models indicate substantial individual differ-
ences both in initial levels and trajectories of functional
abilities, cognition, and depressive symptoms. Such




Intercept (level) Linear slope Quadratic slope
Intercept (SE) Variance (SE) Intercept (SE) Variance (SE) Intercept (SE) Variance (SE)
Unconditional univariatea
BDRS 3.430 (0.093)** 3.783 (0.283)** 1.679 (0.103)** 4.054 (0.339)** –0.024 (0.019) 0.112 (0.012)**
mMMS 37.699 (0.284)** 37.874 (2.617)** –5.181 (0.296)** 34.209 (2.808)** 0.159 (0.057)* 0.947 (0.105)**
CUSPAD 0.771 (0.044)** 0.505 (0.070)** 0.012 (0.036) 0.151 (0.042)** –0.007 (0.007) 0.006 (0.002)**
Conditional multivariate
BDRS 3.621 (0.191)** 3.219 (0.279)** 1.461 (0.221)** 4.061 (0.358)** –0.014 (0.041) 0.110 (0.012)**
mMMS 38.654 (0.582)** 34.045 (2.583)** –5.248 (0.625)** 33.808 (2.914)** 0.095 (0.120) 0.906 (0.101)**
CUSPAD 0.943 (0.090)** 0.497 (0.062)** –0.024 (0.077) 0.167 (0.041)** –0.008 (0.016) 0.007 (0.002)**
SE, standard error; BDRS, Blessed Dementia Rating Scale (range: 0 to 16); mMMS, modified Mini Mental State Exam (range: 0 to 57);
CUSPAD, Columbia Scale for Psychopathology in Alzheimer’s Disease (range: 0 to 4);
aParameters estimated in three separate univariate models;
∗p < 0.05; ∗∗p < 0.001.
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Fig. 1. Estimated growth curves from the univariate models. Dotted lines represent sample means; solid lines represent model-estimated means.
Y axes display full ranges for each scale so that relative differences between symptom types can be appreciated. BDRS, Blessed Dementia
Rating Scale; mMMS, modified Mini Mental State Exam; CUSPAD, Columbia Scale for Psychopathology in Alzheimer’s disease.
Conditional multivariate model
The three best-fitting univariate LGC models
were combined into a single multivariate model, and
four time-invariant predictors measured at baseline
(i.e., age, gender, education, and recruitment site)
were added. First, a transition model in which
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neither cross-domain relationships between latent
variables nor associations involving the covariates
was estimated. In line with the univariate models,
associations between latent variables within a domain
were permitted. The transition model provided the fol-
lowing fit statistics: χ2(788) = 2052.182 (p < 0.001);
AIC = 57513.757; BIC = 57819.616; CFI = 0.894;
TLI = 0.895 and RMSEA = 0.056 (0.053, 0.059).
Figure 2 presents a schematic representation of the
conditional multivariate model, which estimated all
possible regression paths and covariances. Compared
to the transition model, fit significantly improved
(χ2(38) = –516.975, p < 0.001). The model pro-
vided the following fit statistics: χ2(750) = 1535.207
(p < 0.001); AIC = 48315.510; BIC = 48723.136;
CFI = 0.934; TLI = 0.932 and RMSEA = 0.045 (0.042,
0.048).
Intercepts shown in the lower panel of Table 2 can be
interpreted as estimated initial values when all covari-
ates are set to 0 (i.e., age = 74; education = 12 years;
gender = male; site = Columbia). As shown, worsening
over time was evident for functional problems and cog-
nitive symptoms after controlling for these variables.
Changes in depressive symptoms over time were not
significant.
Associations between the factors in the conditional
model are shown in Table 3. After controlling for the
covariates, initial levels predicted subsequent changes
within cognition and function domains. Indepen-
dent of these associations, initial levels of functional
problems and cognitive symptoms were correlated.
Worse initial cognitive status was also associated with
faster subsequent functional decline, and vice versa.
Rates of decline in functional and cognitive status
were correlated between individuals (see Table 3) as
well as coupled within individuals (standardized esti-
mate = –0.207; S.E. = 0.021; p < 0.001). Higher level of
depressive symptoms was associated with worse ini-
tial functioning and faster subsequent cognitive and
functional decline.
Older age was independently associated with greater
initial functional disability (standardized parameter
estimate = 0.28; SE = 0.05; p = 0.001) but slower cog-
nitive decline (standardized parameter estimate = 0.25;
SE = 0.05; p = 0.001) and less worsening of depressive
symptoms. Female gender was associated only with
lower initial mMMS scores (standardized parameter
estimate = –0.16; SE = 0.05; p = 0.001). Lower level of
education was associated with lower cognitive status
at baseline (standardized parameter estimate = 0.21;
SE = 0.05; p < 0.001) but not with the average rate
of cognitive decline. Participants enrolled at differ-
ent recruitment sites differed only in initial depressive
symptoms.
Influence of attrition and medication use
In order to determine whether attrition influenced
the results, a variable reflecting the participation in
the 12th assessment was added to the multivariate
model. In addition to worse initial levels of cognition
and function, participants who did not complete all
5.5 years of follow-up exhibited accelerated cognitive
decline (standardized parameter estimate = –0.238;
p < 0.001) and more rapid increases in functional
problems (standardized parameter estimate = 0.186;
p < 0.001). Importantly, inclusion of this variable did
not alter the pattern of associations summarized in
Table 3.
The potential influence of anti-dementia medica-
tions was investigated in the subset of 265 participants
recruited after 1997 because only six of the 252
participants recruited during the earlier wave took
a prescription medication for dementia. A variable
reflecting use of anti-dementia medication at any point
during the 5.5-year study period was added to the
three univariate models for function, cognition, and
depressive symptoms. Anti-dementia medication use
was not associated with initial levels or rates of change
for depressive symptoms or cognition. Anti-dementia
medication use was associated with lower initial lev-
els of functional problems (unstandardized parameter
estimate = –0.78; p = 0.01), but not with rates of change
in functioning. Thus, anti-dementia medication use did
not appear to influence the trajectories of any outcomes
of interest.
In order to determine whether antidepressant use
influenced the results, a variable reflecting use of
an antidepressant at any point during the 5.5-year
study period was added to the multivariate model
estimated in the full sample. Antidepressant use was
associated with higher initial levels of depressive
symptoms (unstandardized parameter estimate = 0.35;
p < 0.001). In addition, antidepressant use was asso-
ciated with better initial cognitive (unstandardized
parameter estimate = 1.45; p = 0.02) and functional
status (unstandardized parameter estimate = –0.42;
p = 0.04). Importantly, antidepressant use was not asso-
ciated with any of the symptom trajectories, and
inclusion of this additional covariate did not alter the
pattern of results described above.
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Fig. 2. Schematic representation of the conditional multivariate latent growth curve model. BDRS, Blessed Dementia Rating Scale; mMMS,
modified Mini Mental State Exam; CUSPAD, Columbia Scale for Psychopathology in Alzheimer’s disease.
DISCUSSION
This longitudinal study of 517 individuals with AD
replicated previous reports from our group that while
functional and cognitive symptoms gradually worsen
over the disease course, depressive symptoms do not
[12]. The main findings from the multivariate latent
growth curve analysis were: 1) cognitive and func-
tional changes were correlated between individuals and
coupled within individuals; 2) worse initial cognitive
status predicted faster subsequent functional decline,
and vice versa; and 3) depressive symptoms were
associated with worse initial functioning and faster
subsequent cognitive and functional decline.
Our finding of a significant longitudinal associ-
ation between functional and cognitive changes in
AD confirms and extends a previous report [7] by
demonstrating that these outcomes are associated both
between and within persons over time in a controlled,
multivariate model. These results also support the use
of the mMMS [15], a measure of global cognitive sta-
tus, as a gross primary outcome in clinical trials and
studies of AD course. Indeed, this measure appears
to exhibit a similar rate of change as an informant-
rated measure of performance ability and therefore can
adequately track the longitudinal course of functional
decline in AD.
The obtained between-persons association between
rates of functional and cognitive changes in our
multivariate model (standardized parameter esti-
mate = –0.72) is very similar to that reported in
a population-based study of AD (r = –0.62) [7].
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Table 3
Standardized between-persons associations between the latent factors in the conditional multivariate model
BDRS mMMS CUSPAD




Quadratic –0.227* –0.894** –
mMMS
Intercept –0.437** –0.345** 0.321** –
Linear –0.203* –0.719** 0.536** 0.417** –
Quadratic 0.235* 0.631** –0.618** –0.471** –0.854** –
CUSPAD
Intercept 0.208* 0.174* –0.158 –0.086 –0.146* 0.197* –
Linear –0.108 0.039 –0.022 0.026 0.073 –0.154 –0.157 –
Quadratic –0.009 –0.149 0.137 0.048 0.055 0.029 –0.068 –0.938** –
BDRS, Blessed Dementia Rating Scale; mMMS, modified Mini Mental State Exam; CUSPAD, Columbia Scale for Psychopathology in
Alzheimer’s disease.
∗p < 0.05; ∗∗p < 0.001.
This between-person association assesses the rela-
tionship between long term trends in cognitive and
functional change. In contrast, the within-person asso-
ciation between these outcomes in our multivariate
model was more modest (standardized parameter esti-
mate = –0.21). This within-person association assesses
whether occasion-specific deviations from cognitive
and functional trends occur together. This finding indi-
cates that the rate at which an individual patient loses
the ability to perform activities of daily living is heav-
ily influenced by factors other than cognitive decline.
For example, our group has previously shown that
delusions, hallucinations, extrapyramidal signs, and
other motor symptoms predict functional abilities and
other important outcomes (e.g., death, nursing home
placement) in AD [23–26]. The present study provides
evidence that depressive symptoms also have prognos-
tic value in AD.
Depressive symptoms were associated not only with
worse functional abilities initially, but also with faster
subsequent cognitive and functional decline. Many
studies, though not all, have shown that depression
increases dementia risk among cognitively-impaired
older adults [2, 3]. Cross-sectional associations
between depression and function have been reported
[5], and a recent study showed an association between
depression and accelerated cognitive decline in AD [6].
Fewer studies have examined the influence of depres-
sion on the functional course of patients diagnosed with
AD.
We have previously shown that functional decline
predicts first episodes of depressive symptoms in
AD [12]. The present finding that initial depressive
symptoms predicted accelerated functional decline
extends this previous work by providing new evidence
that the association between depressive symptoms and
functioning may be bi-directional in AD. That is, the
loss of functional ability may trigger a reactive depres-
sive episode [12], and initial depressive symptoms
may herald a more aggressive course of cognitive
and functional decline. Thus, depressive symptoms in
AD may not solely represent a psychological reaction
to cognitive or functional decline. Similar results
have also been reported in cognitively intact older
adults [27].
The associations between depressive symptoms and
functioning were independent of cognition. Thus,
depressive symptoms appeared to negatively influence
functioning directly in this cohort of AD patients.
Depressive symptoms were also independently related
to cognitive decline. This pattern of findings suggests
that the pathophysiologic processes leading to depres-
sive and cognitive symptoms in AD may be partially
overlapping. In previous studies, depressive symptoms
in the context of dementia have been linked to pathol-
ogy within the brain stem and substanta nigra and to
reduced cortical norepinephrine [28, 29].
A limitation of this study is the inclusion of only
a subset of variables associated with cognition and
function due to modeling constraints. The included
covariates were chosen based on the extant literature as
well as on significant univariate associations with the
outcome variables in this sample. Other variables have
been examined in previous reports from our group.
For example, we have previously shown that APOE
genotype is not associated with depressive symptoms
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in this cohort [30]. Another limitation is our use of
a single screening measure to assess cognitive symp-
toms (i.e., the mMMS). A more complete cognitive
battery would have allowed for exploration of how
depressive symptoms influence changes in different
cognitive domains. For example, it is possible that
the association between initial depressive symptoms
and functional decline may reflect executive deficits.
Indeed, executive functioning is not fully assessed by
the mMMS. It should also be noted that compared to
participants assessed at the 5.5-year visit, those who
were not assessed at this occasion exhibited worse cog-
nitive and functional status at baseline and accelerated
cognitive and functional decline. However, inclusion of
a variable reflecting drop-out did not alter the pattern
of results.
Strengths of this study include its use of latent
growth curve modeling, as the examination of both ini-
tial levels and trajectories of symptoms provided more
comprehensive evidence regarding their longitudinal
associations. Another major strength is the modeling
of three outcome variables in a single model, which
allowed for more precise estimates of unique associ-
ations and improved upon previous studies in which
models contained single outcome variables.
In conclusion, this study provides evidence that cog-
nitive and functional symptoms travel together in AD.
Results also suggest that cognitive decline predicts
later functional decline, highlighting the importance
of cognitive assessments for functional prognosis.
Finally, disease progression appears to be heavily
influenced by non-cognitive factors, as depressive
symptoms predicted accelerated cognitive and func-
tional decline independently.
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